An improved formulation of Moberg Pharma’s OTC product for the treatment of fungal nails, sold in the U.S. under the Kerasal Nail® brand, recently received a patent from the European Patent Office, according to Moberg. The patent expires in 2034.
The corresponding U.S. patent was also granted earlier this spring and Moberg Pharma is pursuing patent approval in all major territories.
“The granted Kerasal Nail patents provide long-term intellectual property protection for our flagship product. It also reconfirms our commitment to bringing innovation to underserved niches and our long term goal to be the leading player in nail fungus,” said Peter Wolpert, CEO of Moberg Pharma AB.
Kerasal Nail® is based on a formulation of compounds and has been shown to improve the appearance of unsightly fungal nails. Kerasal Nail is applied to the damaged nail using a silicone tip applicator. Its efficacy and safety have been documented in several clinical trials including more than 600 patients.
Source: Moberg Pharma